Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Northwestern University
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have a histologically or cytologically confirmed cancer diagnosis for which EGFRI treatment is indicated
Initiation of topical steroids or control treatment within 3 days of initiation of cetuximab, erlotinib, panitumumab, or afatinib
Patients must be age ≥ 18 years.
Life expectancy of greater than 6 weeks
Patient able to use topical medications reliably and complete questionnaires with assistance if needed
Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study.
You may not be if
Patients who have used systemic or topical steroids within 7 days of trial registration, or start systemic or topical steroids for reasons unrelated to trial during the 6-week follow up period
Patients who have used antibiotics within 7 days of trial registration, or start antibiotics for other conditions during the 6-week follow up period
History of allergic reactions to topical steroids
Patients with any rash at the time of study registration
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Patients using any other topical medications in the treatment areas (face, chest, or back).
Clareo Health | A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption
